As of 2025-11-07, the Relative Valuation of Fulcrum Therapeutics Inc (FULC) is (18.10) USD. This relative valuation is based on P/E multiples. With the latest stock price at 7.65 USD, the upside of Fulcrum Therapeutics Inc based on Relative Valuation is -336.7%.
The range of the Relative Valuation is (17.61) - (18.76) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 14.7x - 18.3x | 16.8x |
| Forward P/E multiples | 17.1x - 19.2x | 18.5x |
| Fair Price | (17.61) - (18.76) | (18.10) |
| Upside | -330.1% - -345.2% | -336.7% |
| Date | P/E |
| 2025-11-05 | -7.66 |
| 2025-11-04 | -8.15 |
| 2025-11-03 | -8.78 |
| 2025-10-31 | -8.52 |
| 2025-10-30 | -8.37 |
| 2025-10-29 | -9.11 |
| 2025-10-28 | -9.74 |
| 2025-10-27 | -9.39 |
| 2025-10-24 | -8.98 |
| 2025-10-23 | -8.71 |
| 2025-10-22 | -8.80 |
| 2025-10-21 | -9.44 |
| 2025-10-20 | -8.98 |
| 2025-10-17 | -8.75 |
| 2025-10-16 | -9.04 |
| 2025-10-15 | -9.38 |
| 2025-10-14 | -8.46 |
| 2025-10-13 | -8.52 |
| 2025-10-10 | -8.75 |
| 2025-10-09 | -9.37 |
| 2025-10-08 | -9.38 |
| 2025-10-07 | -9.00 |
| 2025-10-06 | -9.25 |
| 2025-10-03 | -8.98 |
| 2025-10-02 | -9.26 |
| 2025-10-01 | -9.08 |
| 2025-09-30 | -8.96 |
| 2025-09-29 | -8.44 |
| 2025-09-26 | -8.61 |
| 2025-09-25 | -8.28 |
| 2025-09-24 | -8.03 |
| 2025-09-23 | -7.16 |
| 2025-09-22 | -7.25 |
| 2025-09-19 | -7.19 |
| 2025-09-18 | -7.34 |
| 2025-09-17 | -7.13 |
| 2025-09-16 | -7.11 |
| 2025-09-15 | -6.88 |
| 2025-09-12 | -6.81 |
| 2025-09-11 | -6.81 |
| 2025-09-10 | -6.81 |
| 2025-09-09 | -7.05 |
| 2025-09-08 | -7.08 |
| 2025-09-05 | -7.46 |
| 2025-09-04 | -6.70 |
| 2025-09-03 | -6.35 |
| 2025-09-02 | -6.24 |
| 2025-08-29 | -6.31 |
| 2025-08-28 | -6.47 |
| 2025-08-27 | -6.45 |